...
首页> 外文期刊>BMB Reports >PRR11 and SKA2 gene pair is overexpressed and regulated by p53 in breast cancer
【24h】

PRR11 and SKA2 gene pair is overexpressed and regulated by p53 in breast cancer

机译:PRR11和SKA2基因对在乳腺癌中过度表达并受p53调控

获取原文
           

摘要

Our previous study found that two novel cancer-related genes, PRR11 and SKA2, constituted a classic gene pair that was regulated by p53 and NF-Y in lung cancer. However, their role and regulatory mechanism in breast cancer remain elusive. In this study, we found that the expression levels of PRR11 and SKA2 were upregulated and have a negative prognotic value in breast cancer. Loss-of-function experiments showed that RNAi-mediated knockdown of PRR11 and/or SKA2 inhibited proliferation, migration, and invasion of breast cancer cells. Mechanistic experiments revealed that knockdown of PRR11 and/or SKA2 caused dysregulation of several downstream genes, including CDK6, TPM3, and USP12, etc. Luciferase reporter assays demonstrated that wild type p53 significantly repressed the PRR11-SKA2 bidirectional promoter activity, but not NF-Y. Interestingly, NF-Y was only essential for and correlated with the expression of PRR11, but not SKA2. Consistently, adriamycin-induced (ADR) activation of endogenous p53 also caused significant repression of the PRR11 and SKA2 gene pair expression. Notably, breast cancer patients with lower expression levels of either PRR11 or SKA2, along with wild type p53, exhibited better disease-free survival compared to others with p53 mutations and/or higher expression levels of either PRR11 or SKA2. Collectively, our study indicates that the PRR11 and SKA2 transcription unit might be an oncogenic contributor and might serve as a novel diagnostic and therapeutic target in breast cancer.
机译:我们先前的研究发现,两个新的与癌症相关的基因PRR11和SKA2构成了肺癌中受p53和NF-Y调控的经典基因对。但是,它们在乳腺癌中的作用和调控机制仍然难以捉摸。在这项研究中,我们发现PRR11和SKA2的表达水平在乳腺癌中被上调并具有负预后价值。功能丧失实验表明,RNAi介导的PRR11和/或SKA2的抑制可抑制乳腺癌细胞的增殖,迁移和侵袭。机理实验表明,PRR11和/或SKA2的敲低导致几个下游基因的失调,包括CDK6,TPM3和USP12等。是的有趣的是,NF-Y仅对PRR11的表达至关重要,而与SRR2的表达无关。一致地,阿霉素诱导的(ADR)内源性p53激活也引起PRR11和SKA2基因对表达的显着抑制。值得注意的是,与其他具有p53突变和/或较高PRR11或SKA2表达水平的人相比,具有PRR11或SKA2表达水平较低的乳腺癌患者以及野生型p53表现出更好的无病生存率。总体而言,我们的研究表明PRR11和SKA2转录单位可能是致癌因素,并且可以作为乳腺癌的新型诊断和治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号